Dexycu

Drug Overview

In the innovative landscape of Ophthalmology, managing inflammation after intraocular surgery is paramount to ensuring high-quality visual recovery. Dexycu represents a sophisticated advancement in post-operative care, specifically designed to address the challenges of patient compliance and ocular tissue trauma. As a potent member of the Corticosteroid drug class, it provides a “dropless” alternative to traditional topical therapy, delivering medication directly where it is needed most at the conclusion of a surgical procedure.

• Generic Name: Dexamethasone intraocular suspension
• US Brand Names: Dexycu
• Route of Administration: Intraocular Injection (Spherically coalesced depot in the posterior chamber)
• FDA Approval Status: FDA Approved

Historically, patients undergoing cataract surgery were required to self-administer multiple steroid drops daily for several weeks. Dexycu transforms this experience by allowing the surgeon to place a single, sustained-release dose inside the eye. This Targeted Therapy ensures that the inflammatory cascade is suppressed immediately, reducing the risk of complications associated with missed doses or improper drop instillation technique.

What Is It and How Does It Work? (Mechanism of Action)

Dexycu utilizes a synthetic glucocorticoid, dexamethasone, which is renowned for its high potency and anti-inflammatory efficacy. The drug functions through a complex biochemical process that shuts down the pathways responsible for ocular swelling, heat, and pain.

At the molecular level, dexamethasone enters the cells and binds to specific glucocorticoid receptors. This binding triggers the production of lipocortins, which are inhibitory proteins. Lipocortins effectively block the enzyme phospholipase A2. This is a critical step because phospholipase A2 is the “gatekeeper” enzyme that releases arachidonic acid from cell membranes. By inhibiting this release, Dexycu prevents the subsequent formation of inflammatory mediators, including prostaglandins and leukotrienes.

Furthermore, the drug is formulated using a proprietary Verisome technology. When the liquid suspension is injected into the aqueous environment behind the iris, it immediately coalesces into a single, tiny spherical depot. This depot does not dissolve instantly; instead, it undergoes a controlled degradation. As it slowly shrinks over approximately 22 to 30 days, it releases a consistent, therapeutic concentration of dexamethasone directly into the anterior segment. This sustained delivery stabilizes the blood-aqueous barrier and prevents the influx of white blood cells (leukocytes) into the eye, ensuring the ocular environment remains quiet and clear during the critical healing phase.

FDA-Approved Clinical Indications

Primary Indication

The primary, FDA-approved indication for Dexycu is the treatment of post-operative intraocular inflammation. It is most commonly utilized following cataract surgery, where it replaces the need for standard steroid eye drops during the first month of recovery.

Other Approved & Off-Label Uses

While its main use is in cataract surgery, surgeons may utilize intraocular corticosteroids in various complex scenarios:

• Complex Cataract Surgery: In cases involving “floppy iris” syndrome or prolonged surgical times where higher inflammation is anticipated.
• Glaucoma Filter Surgery: Occasionally used off-label to modulate the healing response and prevent excessive scarring around a new drainage bleb.
• Uveitic Patients: To provide an extra layer of inflammatory protection in patients with a history of chronic uveitis undergoing lens replacement.

Primary Ophthalmology Indications:

• Stabilization of the Blood-Aqueous Barrier: Preventing the leakage of protein and cells into the anterior chamber (flare and cells).
• Prevention of Cystoid Macular Edema (CME): Reducing the chemical signals that can cause the central retina to swell after surgery.
• Visual Rehabilitation: Ensuring a clear optical pathway by preventing fibrin formation and pupillary membranes.

Dosage and Administration Protocols

Unlike traditional medications, Dexycu is not handled by the patient. It is administered strictly by a surgeon in a sterile operating room environment.

Indication	Standard Dose	Frequency
Post-operative Inflammation	0.005 mL of 9% suspension (517 mcg)	Single dose at the conclusion of surgery

Specific Instructions for Administration

• Preparation: The surgeon or surgical assistant prepares the dose using a specialized kit, which includes a specific syringe and a vented needle for precise measurement.
• Placement: The medication is injected into the posterior chamber, typically behind the iris in the inferior ciliary sulcus.
• Technique: The surgeon ensures the depot is properly positioned so it does not interfere with the newly implanted intraocular lens (IOL) or the visual axis.
• Post-Injection: No tapering is required by the patient, as the Verisome technology naturally tapers the drug delivery as the depot degrades.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical trials for Dexycu between 2020 and 2026 have demonstrated its non-inferiority—and in many cases, its practical superiority—to topical steroid regimens due to the elimination of “compliance error.” In pivotal Phase 3 trials, a significantly higher percentage of patients treated with Dexycu achieved a “cleared” anterior chamber (zero cells) by post-operative day 8 compared to those using a placebo.

Key numerical data points include:

• Inflammatory Clearance: Approximately 60% to 63% of patients show a total absence of anterior chamber cells by the first week.
• Visual Stabilization: Mean change in Best Corrected Visual Acuity (BCVA) remains consistent with successful surgical outcomes, with no significant difference in final visual letters compared to topical steroids.
• Retinal Health: Optical Coherence Tomography (OCT) monitoring shows that Central Retinal Thickness (CRT) remains within normal physiological limits, with a low incidence of post-operative macular swelling.

This drug is efficacious in preventing vision loss because it provides a steady state of medication. Unlike drops, which have high “peaks” and low “troughs” in concentration, the sustained-release depot maintains a protective environment 24 hours a day, preventing inflammatory “breakthrough” that could lead to scarring or secondary glaucoma.

Safety Profile and Side Effects

Black Box Warning: There is NO BLACK BOX WARNING for Dexycu. However, as with any intraocular steroid, it requires vigilant monitoring.

Common Side Effects (>10%)

• Increased Intraocular Pressure (IOP): Steroid-induced IOP spikes are the most common concern, as corticosteroids can decrease the ease of fluid drainage from the eye.
• Ciliary Congestion: Mild redness or a heavy sensation in the eye during the first few days.
• Blurred Vision: Temporary blurring as the eye recovers from both the surgery and the presence of the medication depot.

Serious Adverse Events

• Endophthalmitis: A severe intraocular infection. While rare, any intraocular injection carries this risk.
• Retinal Detachment: A potential surgical complication that requires immediate intervention.
• Secondary Glaucoma: Permanent damage to the optic nerve if an IOP spike is not managed with pressure-lowering drops.
• Depot Migration: In rare cases, the spherical depot may move into the visual axis, causing a temporary “floater” or blurred spot until it dissolves.

Management Strategies

Surgeons utilize sterile administration techniques to prevent infection. Post-operative protocols include mandatory Tonometry (IOP measurement) at the 1-day, 1-week, and 1-month check-ups. If a “steroid-response” pressure spike occurs, it is typically managed easily with a temporary course of topical pressure-lowering drops.

Research Areas

Direct Clinical Connections

Active research is currently focusing on the interaction between intraocular corticosteroids and goblet cell density. Since Dexycu is “dropless,” it avoids the preservatives (like BAK) found in many eye drops that can damage the ocular surface. Research indicates this may be significantly better for patients with pre-existing Dry Eye Disease (DED) or chronic surface irritation.

Generalization

From 2020 to 2026, research has expanded into Novel Delivery Systems such as biodegradable implants and gene therapy. Dexycu’s success has paved the way for “combination dropless surgery,” where both a steroid and an antibiotic are delivered at once. There is also ongoing work in developing Preservative-Free sustained-release medications for chronic conditions like glaucoma to reduce the daily burden on patients.

Disclaimer: Information in this section regarding the preservation of goblet cell density due to the absence of preservatives and the development of combination steroid-antibiotic dropless systems is considered investigational until definitive clinical evidence is established. While these concepts are at the forefront of Ophthalmology research in 2026, they are not applicable to practical clinical scenarios.

Severe Disease & Surgical Integration

Studies are investigating Dexycu’s efficacy in preventing blindness in end-stage glaucoma patients who must undergo cataract surgery. These patients are at high risk for “IOP spikes” and “post-op spikes,” so researchers are refining the dosage to balance inflammatory control with pressure safety.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Baseline Visual Acuity, Tonometry (IOP), and a thorough Slit-lamp exam.
• Ocular Imaging: Macular OCT is performed to ensure the retina is healthy before surgery.
• Screening: Identifying “steroid responders” who have a history of high eye pressure when using steroids.

Monitoring and Precautions

• Vigilance: Doctors monitor for “rebound” inflammation as the depot completely disappears around week four.
• Lifestyle: Patients should wear UV protection (sunglasses) to manage post-operative light sensitivity and maintain eyelid hygiene.

“Do’s and Don’ts” list

• DO attend all follow-up appointments, especially the 1-week and 1-month checks.
• DO contact your surgeon if you see a sudden increase in “floaters” or a curtain over your vision.
• DON’T rub your eye, as this can increase pressure and disrupt surgical incisions.
• DON’T worry if you see a small, clear bubble in your vision; this is often the medication depot and will dissolve on its own.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Always consult with your board-certified Ophthalmologist regarding surgical options and post-operative medications. If you experience sudden pain or loss of vision after surgery, seek emergency medical attention immediately.